Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts

  • neetu
    replied
    Genexplain recently uploaded a white paper explaining the difference between TRANSFAC and JASPAR. It seems when we use TRANSFAC there are chances that we don't miss important matrices that play a role in the regulation of genes of interest. The white paper link can be found here:



    Old thread but maybe it is still useful to someone.

    Leave a comment:


  • mbblack
    replied
    Sorry, but I have no idea what to tell you to tell your supervisor as far as what to spend his or her research money on.

    Have you tried using JASPAR yet? Are the results unsatisfactory in some way?

    Have you tried the free trial for TRANSFAC and compared the results to JASPAR?

    Does anybody else in your school use TRANSFAC so you could check out the full version?

    As I already said, as far as I know, its pretty much a toss up as to which is "better" (and I'm not even clear on how you would define "better" in such a case anyway).

    Leave a comment:


  • siddharthsameer
    replied
    Thanks for your reply. Could you please tell me what would be the convincing statment to ask my supervisor to give me the fund for the TRANSFAC license. Please tell me as I am student and very new in this field.
    thanks

    Originally posted by mbblack View Post
    Pretty much what JASPAR (not Jasper) says right on their web site. The really major difference being JASPAR is open source whereas TRANSFAC is a commercial for-fee access preduct owned by BioBase (which is owned by Qiagen).

    JASPAR also claims they have superior quality of curation and less redundancy. I'm not sure how true that is, since TRANSFAC is also curated and one of its selling points is you are paying for the professional quality of their data and tools. It is also something I think is inherently speculative, since there is no way to compare the two as to which is "better" (and if so, in what sense of the word?).

    Note that the free, limited version of TRANSFAC is definitely not comparable to JASPAR as it is out of date and very limited. However, I'd think that the for-fee TRANSFAC Pro release and tools is probably pretty much on a par with JASPAR.

    Leave a comment:


  • mbblack
    replied
    Pretty much what JASPAR (not Jasper) says right on their web site. The really major difference being JASPAR is open source whereas TRANSFAC is a commercial for-fee access preduct owned by BioBase (which is owned by Qiagen).

    JASPAR also claims they have superior quality of curation and less redundancy. I'm not sure how true that is, since TRANSFAC is also curated and one of its selling points is you are paying for the professional quality of their data and tools. It is also something I think is inherently speculative, since there is no way to compare the two as to which is "better" (and if so, in what sense of the word?).

    Note that the free, limited version of TRANSFAC is definitely not comparable to JASPAR as it is out of date and very limited. However, I'd think that the for-fee TRANSFAC Pro release and tools is probably pretty much on a par with JASPAR.

    Leave a comment:


  • Difference between TRANSFAC and JASPER database

    Hello can someone tell me what is the main difference between TRANSFAC and JASPER database.

    thanks for your reply in advance
    regards

Latest Articles

Collapse

  • SEQadmin2
    Multiomic Liquid Biopsy: What DNA/RNA Panels Reveal That DNA Alone Can’t
    by SEQadmin2



    Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?

    Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating
    ...
    10-14-2026, 09:55 AM
  • SEQadmin2
    New Genomics Technologies Take Aim at Long-Standing Limits
    by SEQadmin2


    Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.

    We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing
    ...
    09-28-2026, 10:25 AM

ad_right_rmr

Collapse

News

Collapse

Topics Statistics Last Post
Started by SEQadmin2, 10-22-2026, 11:13 AM
0 responses
26 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 10-22-2026, 10:48 AM
0 responses
20 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 10-15-2026, 10:52 AM
0 responses
36 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 10-14-2026, 05:39 AM
0 responses
43 views
0 reactions
Last Post SEQadmin2  
Working...